Skip to main content

Basel is very open to newcomers

| News

Basel is very open to newcomers


In an interview that was published in “network mag”, Novartis CEO Vas Narasimhan talks about diversity at Novartis and his positive experience of living in Basel.

Vas Narasimhan (image: Novartis)

In 2018, Vas Narasimhan became CEO of pharmaceutical company Novartis. The American, his wife and two sons have lived in Basel for more than ten years. With “network mag”, Vas Narasimhan shared his view on diversity and inclusion and on living in Basel.

Asked about his experience of living in Switzerland, Narasimhan answers: “Nestled in the heart of Europe, I’ve found that Basel is very internationally minded and open to newcomers. This may be because it is a border town and because historically immigrants have found their way to Basel, including some of the founders of the pharmaceutical and chemical companies that have become global leaders. When you think that Novartis and our predecessor companies have been shipping goods from here for over 250 years, you realize how closely this place has been linked to the world over the past centuries. My experience here has only been positive.”

Narasimhan also told the magazine that Basel became his and his family’s home by now. He also revealed what he likes best about living in Switzerland: “Switzerland is a great place to live, and I am very happy here. The landscape is breathtaking, and there is good social and healthcare infrastructure. The overall quality of life here is very high. There’s a lot to love!”

Novartis is one of the biggest pharmaceutical companies in the world. It’s global headquarters are located in Basel. More than 104’000 employees work for Novartis around the globe. In 2020, the company had a turnover of 48.7 billion dollars and reported a net profit of 8.1 billion dollars.

You may also be interested in

Roche investing an additional 1.2 billion Swiss francs in Basel

Roche will be putting an additional 1.2 billion Swiss francs towards the renovation of its site in Basel. This investment...
Read More

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

Paradigm shift in pain management

Pain is a crucial sensation for survival, but it can also drive us to depression and long-term suffering if not...
Read More

Investors stump up 3.7 million Swiss francs in Onena Medicines

Onena Medicines has secured an investment of 3.7 million Swiss francs. The portfolio company of the biotech startup incubator BaseLaunch...
Read More